Active pharmaceutical ingredients (API) and non-ready-to-use medicines (formula magistralis) are ultimately used to improve the quality of life and health of patients. Since health is man's greatest asset, we make no compromises when it comes to quality. Canexis is committed to bringing the highest quality cannabinoids to the market for medical purposes.

To ensure this, we work consistently in accordance with the EU or PIC/S-GMP regulations. In addition, we implement the requirements of the following works:

• Pharmacopeia Europea (Ph. Eur.)
• Pharmacopeia Helvetica (Ph. Helv.)
• German Pharmacopoeia (DAB)
• Medicinal Products Act (HMG)
• German Medicines Codex (DAC-NRF)
  
  

But quality doesn't just come from working according to regulations. In order to achieve the best quality, significantly more is necessary. The demand for the highest quality must be lived – by everyone involved along the value chain. You also have to understand and know what you are doing in order to do the right things in the right way. The best quality therefore requires uncompromising adherence to the regulations, great self-discipline and high demands on yourself, cross-value chain collaboration and a lot of knowledge.

For us, quality doesn’t just start with the last process steps. It is right at the beginning, namely with the seed. The selection and choice of the highest quality varieties is the first relevant step, followed by sustainable outdoor or greenhouse cultivation with our partners. We work with you to create guidelines and specifications. The plants are always produced according to GACP and are regularly checked by Canexis throughout the entire cycle. Even after the harvest itself, nothing is left to chance: we always store and transport the raw materials in a controlled environment. When the raw material arrives at Canexis, we subject it to a pharmacopeia-compliant quality control. It is then processed at our production site in accordance with the strict requirements of pharmacopoeias and GMP regulations and refined up to its final destination - active pharmaceutical ingredients or non-ready-to-use medicinal products.